LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer

By LabMedica International staff writers
Posted on 25 May 2023
Print article
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)

Diesse Diagnostica Senese S.p.A. (Rigoni, Italy) is unveiling its new innovative immunochemistry analyzer, the CHORUS EVO, at this year's WorldLab-EuroMedLab.

The cutting-edge DIESSE CHORUS line comprises a compact instrument and consumables for immunometric assays. Known for simplicity, high-quality mono-test results, and reliability, the CHORUS line is the perfect tool for conducting small-batch diagnostic tests. Its design ensures maximum flexibility in managing the workflow of a clinical laboratory. Even when lab automation isn't viable, the CHORUS line stands out as a go-to solution for immediate, simple, and accurate testing. Its mono-test format facilitates operational efficiency and minimal waste, which is a boon for smaller test volumes. This makes CHORUS an excellent resource for Physician Office Laboratories (POLs) and other diagnostic laboratories, providing them with analytical quality and operational efficiency.

In line with developing instruments featuring cutting-edge technology that meet Italian design and its vision of "Diagnostics Evolution", DIESSE has now unveiled the CHORUS EVO immunochemistry analyzer. CHORUS EVO is a new-generation analytical instrument that integrates innovative digital technology, paving the way for the integration of artificial intelligence functions. In order to achieve this, DIESSE is collaborating with the SAIHUB consortium, a network of companies that specialize in applying artificial intelligence in life sciences.

Their collaborative effort is directed towards creating a data platform, to which the instruments will be connected, facilitating a large-scale data accumulation. This setup will enable direct digital communication between the company and individual instruments, making it possible for the company to monitor the instruments through the data platform. Moreover, it will harness beneficial artificial intelligence functions to train the analyzers to enhance their performance and employ predictive diagnostics to preempt machine downtime. The project also plans to incorporate computer vision systems rooted in artificial intelligence to further optimize the diagnostic capabilities of the instruments.

Related Links:
Diesse Diagnostica Senese Spa

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.